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Glutathione-doxorubicin conjugate expresses potent
cytotoxicity by suppression of glutathione S-transferase
activity: comparison between doxorubicin-sensitive and
-resistant rat hepatoma cells
T Asakura, K Ohkawa, N Takahashi, K Takada, T Inoue and S Yokoyama
Department of Biochemistry (I), Jikei University School of Medicine, Tokyo 105, Japan
Summary The cytotoxic mechanism of a conjugate of doxorubicin (DXR) and glutathione (GSH) via glutaraldehyde (GSH-DXR) was
investigated using DXR-sensitive (AH66P) and -resistant (AH66DR) rat hepatoma cells. GSH-DXR accumulated in AH66DR cells as well as
in AH66P cells without efflux by P-gp and exhibited the potent cytocidal activity against both cells compared with DXR. To examine whether
thiol from GSH-DXR affected the expression of cytotoxicity, two conjugates of DXR, with modified peptides containing alanine or serine
substituted for cysteine in GSH were prepared and their cytotoxicities determined. Substitution of these amino acids for cysteine resulted in
an approximately two- to fourfold reduction in cytotoxic activity against both cell lines compared with the effect of GSH-DXR. Depletion of
intracellular GSH by treatment of both cells with buthionine sulphoximine did not change the cytotoxic activity of DXR, BSA-DXR or GSH-
DXR. By co-treating the cells with tributyltin acetate, an inhibitor of glutathione S-transferase (GST), and either DXR, BSA-DXR orGSH-DXR,
the cytotoxicity was markedly increased. Interestingly, GSH-DXR showed non-competitive inhibition of GST activity and its IC50value was
1.3 ,UM. These results suggested that the inhibition of GST activity by GSH-DXR must be an important contribution to the expression of potent
cytotoxicity of the drug.
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Several mechanisms, either alone or in combination, have been
proposed to explain cellulardrug resistance. They are: overproduc-
tion of multidrug resistance (MDR)-related 170-kDa P-glycopro-
tein (P-gp) (Riordan et al, 1985; Endicott and Ling 1989); increase
in the glutathione (GSH) content (Hamilton, etal, 1985; Russo and
Mitchell, 1985); enhanced expression ofglutathione S-transferase
(GST) (Batist et al, 1986; Black et al, 1988; Lewis et al, 1988; Tew
1994); and change in topoisomerase II activity (Beck, 1989;
Isabella et al, 1991) in the resistant cells.
It has been reported that drug resistance is reversed by a variety
of substances, such as an inhibitor of the P-gp efflux pump and
anti-P-gp antibody for MDR (Tsuruo et al, 1982; FitzGerald et al,
1987; Twentyman et al, 1987; Tsuruo et al, 1989; Chen et al,
1991), and an inhibitor of GST or of GSH synthase in the
GSH/GST detoxification system (Tew et al, 1988; Petrini et al,
1993; Lee et al, 1996). We have reported that a conjugate ofDXR
with bovine serum albumin (BSA) (BSA-DXR) reversed MDR
and markedly increased cytotoxicity against several MDR cell
lines (Hatano et al, 1993; Ohkawa et al, 1993a,b); we have also
reported that the liberation of the degraded active adducts with a
molecular weight of approximately 2 kDa of BSA-DXR by lyso-
somal breakdown was essential for the expression of cytotoxicity
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(Takahashi et al, 1996). Moreover, a recent study revealed that
DXR conjugated to GSH (GSH-DXR) with rapid intracellular
accumulation without efflux improved the cytotoxicity against
MDR cells (Asakura et al, 1997). As the GSH-DXR exhibited
potent cytotoxicity against not only MDR-cells but also DXR-
sensitive cells, the effect ofGSH-DXR on GST activity was exam-
ined using DXR-sensitive and -resistant rat hepatoma cells.
MATERIALS AND METHODS
Materials
DXR was obtained from Kyowa Hakko Kogyo (Tokyo, Japan).
BSA, GSH, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazorium
bromide (MTT), verapamil, 1-chloro-2,4-dinitrobenzene (CDNB),
tributyltin acetate, D,L-buthionine-S,R-sulphoximine (BSO) and
o-phthalaldehyde were obtained from Sigma Chemical (St Louis,
MO, USA). Dowex 50Wx8, glycylglycylglycine (triGly) and
glutaraldehyde were purchased from Nakarai Tesque (Kyoto,
Japan). y-Glutamylalanylglycine (EAG) and y-glutamylseryl-
glycine (ESG) were obtained from Sawaday Technology (Tokyo,
Japan). All other chemicals were ofanalytical grade.
Cell lines
The rat ascites hepatoma cell line AH66P and DXR-resistant
mutant subline AH66DR (10gIM DXR resistance), were cultured
with RPMI-1640 medium containing 10% heat-inactivated fetal
bovine serum (growth medium) under conventional conditions
(Ohkawa et al, 1993a,b; Takahashi et al, 1996; Asakura et al, 1997).
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Table 1 The effect of verapamil (VPL) on 50% growth-inhibitory
concentration (GIC50) values for peptide-conjugated DXR and the drug
accumulation rates in AH66P and AH66DR cells.
GIC, values (nM) Drug accumulation rates (%)
AH66P AH66DR AH66P AH66DR
Drugs -VPL -VPL +VPL -VPL -VPL +VPL
DXR 600 32 000 900 17.1 2.5 14.3
+90 ±15 000 ±190 ±2.0 ±0.8 ±2.3
BSA-DXR 30 600 40 11.3 9.7 12.1
+4.0 ±90 ±15 ±1.8 ±0.7 ±1.5
TriGly-DXR 500 20 000 700 16.9 3.4 13.9
+70 ±5 000 ±210 ±1.9 ±1.1 ±1.3
GSH-DXR 3.5 80 16 15.0 13.4 14.0
+1.1 ±16 ±4 ±0.9 ±1.6 ±1.1
EAG-DXR 7.8 240 80 14.2 13.3 14.4
+1.5 ±40 ±10 ±2.6 _2.1 i2.0
ESG-DXR 10.0 300 90 13.9 13.1 14.1
±2.2 ±50 ±12 ±3.0 ±1.9 ±1.7
Incubation was carried out in the presence or absence of 5gM verapamil
(VPL). GIC50 values were expressed as equivalent concentrations of DXR.
Results are means ± s.d. (four or five independent experiments). The drug
accumulation rate was expressed as intracellular DXR relative to DXR added
to the medium during 24 h of incubation. For details see Materals and
methods.
Conjugation of DXR with various peptides
An aliquot (1 mg) ofeach peptide and 0.5 mg ofDXR in 0.5 ml of
0.15 M sodium chloride containing 0.1% glutaraldehyde was
incubated at room temperature for 30 min. After incubation, the
mixture was applied to Dowex 50Wx8 (H+ form, 5 x 15 mm), and
the conjugate of DXR with each peptide was eluted with 0.15 M
sodium chloride. The eluate was neutralized immediately with
sodium hydroxide. BSA-DXR was prepared as described previ-
ously (Hatano et al, 1993; Ohkawa et al, 1993a,b). All drugs were
filter-sterilized by a 0.45-,um syringe filter (Coming Coster,
Tokyo, Japan). The concentration of DXR was measured by
absorbance at 495 nm.
Cytotoxicity of DXR conjugates
To assess the growth-inhibitory effect of the conjugates, viable
AH66P and AH66DR cells (2 x 104) were cultured continuously
for 96 h in a 48-well culture plate (Coming Coster) with 0.5 ml of
growth medium containing graded equivalent concentrations of
DXR in the presence or absence of5giM verapamil (an inhibitor of
the P-gp efflux pump), 4 ,UM BSO (an inhibitor ofGSH synthase)
or 0.3 gM tributyltin acetate (an inhibitor of GST). After incuba-
tion, viable cells were determined with the colorimetric assay
using MTT as described previously (Mosmann, 1983), and the
results were expressed by the following equation: survival
rate (%) = 100 x (absorbance at 570 nm ofthe drug-exposed cells)/
(absorbance at 570 nm ofthe non-treated control cells).
Intracellular accumulation of drugs
After 24 h incubation of the cells (5 x 105 cells per ml of growth
medium) with 5 gM DXR or conjugates in the presence or absence
of 5 gM verapamil under conventional culture conditions, the cells
were scraped and washed with 5 ml ofcold 0.15 M sodium chloride
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Figure 1 Cytotoxicity of DXR and conjugates of DXR with peptides against
AH66P and AH66DR cells. Cytotoxicity was expressed as equivalent
concentrations of DXR vs survival rate. TheGICG5 value of each drug is
shown in Table 1. -X-, DXR; -A-, BSA-DXR; -A-, triGly-DXR; -0-, GSH-
DXR; -0-, EAG-DXR; -E-; ESG-DXR
three times, then sonicated mildly in 10 mm Tris-HCl (pH 7.4).
The intracellular DXR was measured by fluorospectrometry as
described previously (Asakura et al, 1997).
Measurement of cellular GSH concentration
After incubation with BSO or GSH-DXR, the collected cells were
suspended in 10 mm sodium phosphate buffer (pH 7.4). The cell
suspension was mixed with 0.1 M perchloric acid and the mixture
(0.2 ml) was centrifuged at 10000 g for 10min. The resultant
supematant was neutralized with sodium hydroxide and incubated
with 2 ml of 0.1 M sodium phosphate buffer (pH 8.2) containing
50 tl of 1% o-phthalaldehyde in methanol at room temperature
for 30 min. After incubation, the mixture was measured by
fluorospectrometry at an emission wavelength of 420 nm with an
excitation wavelength of350 nm (Jocelyn et al, 1970).
Assay of GST activity
The scraped and washed cells were sonicated in 10 mm sodium
phosphate buffer (pH 7.4) and the resultant suspension was used
as the enzymatic source. GST activity was measured at 340 nm
(£ = 9600) in 1 mm CDNB, 1 mm GSH and 0.1 M sodium phos-
phate buffer (pH 6.5) at 37°C for 10 min in the presence or
absence oftest drugs (Habig et al, 1974).
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Figure 2 Cytotoxicity of DXR, BSA-DXR and GSH-DXR against AH66P
and AH66DR cells cotreated with 0.3gM tributyltin acetate (TBSn). -A-,
DXR; -A-, DXR-TBSn; -i-, BSA-DXR; --, BSA-DXR + TBSn; -0-, GSH-
DXR; -0-, GSH-DXR + TBSn
Protein determination
The protein concentration was assayed by a Bio-Rad protein assay
kit using BSA as the standard.
RESULTS
Cytotoxicity and accumulation of drugs in the cells
As shown in Figure 1, GSH-DXR exhibited potent cytotoxicity to
both AH66P andAH66DR cells compared with DXR, triGly-DXR
or BSA-DXR. In AH66DR cells, BSA-DXR and GSH-DXR accu-
mulated withoutefflux by P-gp and the addition of5 ,UM verapamil
caused only a slight increase in the intracellular accumulation of
both conjugates (Table 1). In contrast, the intracellular accumula-
tion of DXR and triGly-DXR was low and treatment of the cells
with verapamil markedly increased the intracellular accumulation
ofthese drugs.
Reduction of cytotoxic activity by removal of thiol from
GSH-DXR
The intracellular accumulation of EAG-DXR or ESG-DXR
reached the same concentration as that of GSH-DXR in both
AH66P and AH66DR cells (Table 1). Unexpectedly, the cytotoxi-
city of EAG-DXR or ESG-DXR was obviously reduced two- or
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Figure 3 Effect of drugs on GST activity in the cell extracts from either
AH66P or AH66DR cells. CDNB (1 mM) and GSH (1 mM) were used as the
substrate. IC50 values of GSH-DXR and EAG-DXR for the GST activity were
1.3 and 10gM respectively in the extract from AH66P cells and 1.2 and 11 AM
respectively in the extract from AH66DR cells. The Lineweaver-Burk plot is
shown in the insert. Results are means ± s.d. (three independent
experiments). x, DXR; 0, BSA-DXR; A, triGly-DXR; *, GSH-DXR; A, EAG-
DXR; E, ESG-DXR
threefold in AH66P cells and three- or fourfold in AH66DR cells
compared with that of GSH-DXR. Moreover, the cytotoxicities of
GSH-DXR, EAG-DXR or ESG-DXR in AH66P cells were 170-,
77- and 60-fold higher, respectively than that of DXR in spite of a
lower accumulation ofthe conjugates compared with DXR.
Decrease in cellular GSH concentration and GST
activity by treatment with GSH-DXR
As the 50% growth-inhibitory concentration value of GSH-DXR
was different between AH66P and AH66DR cell lines as shown
in Table 1, GSH concentration and GST activity in each cell line
were measured at drug concentration to exhibit almost the same
cytotoxicities. Treatment of AH66P cells with 10 nm GSH-DXR
led to a time-dependent decrease in GSH concentration and the
level after 48 h of incubation was reduced to 55% of the initial
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concentration of GSH (14.06-7.76 nmol mg-' protein). However,
treatment of AH66DR cells with 100 nM GSH-DXR did not
reduce the intracellular concentration of GSH (data not shown).
On the other hand, the treatment of both AH66P and AH66DR
cells with GSH-DXR did not induce any significant decrease in the
activity of GST compared with the GST activity in non-treated
control cells (data not shown).
Enhancement of cytotoxic efficacy of drugs by
treatment with BSO or tributyltin acetate
The 96-h treatment of AH66P and AH66DR cells with 4 gM BSO
reduced the intracellular GSH concentration from 14.75 to
2.94 nmol mg-' protein of whole-cell homogenate and from 30.45
to 5.16 nmol mg-' protein of whole-cell homogenate respectively.
Under these conditions, no significant change was observed in the
sensitivity of both cell lines to DXR, BSA-DXR and GSH-DXR
(data not shown). On the other hand, treatment with 0.3 gM trib-
utyltin acetate increased the cytotoxicity of DXR, BSA-DXR and
GSH-DXR 3.3-, 3.5- and 2.3-fold respectively in AH66P cells and
3.6-, 8.6- and 2.3-fold respectively in AH66DR cells (Figure 2).
The IC 5 value of tributyltin acetate for GST activity was 3 gM
(data not shown).
Inhibitory effect of conjugates on GST activity
Incubating the cell extracts from either AH66P or DR cells with
the conjugates, GSH-DXR and EAG-DXR inhibited the enzyme
activity of GST (Figure 3). IC50 values of GSH-DXR and EAG-
DXR for the enzyme activity were 1.3 and 10gM respectively, in
the extract from AH66P cells and 1.2 and 11JIM respectively in
the extract from AH66DR cells. GSH-DXR acted as a non-
competitive inhibitor to the enzyme, GST in both cell lines (Figure
3, insert). DXR, triGly-DXR, BSA-DXR and ESG-DXR showed
no significant inhibition ofthe GST activity up to 10gM ofequiv-
alent concentrations of DXR.
DISCUSSION
GSH-DXR exhibited a superior cytotoxic efficacy against both
DXR-sensitive and -resistant cells relative to DXR. Our recent
report demonstrated that GSH-DXR accumulated in MDR cells
with minimal efflux by P-gp and the accumulation of GSH-DXR
in both AH66P and AH66DR cells showed the same uptake
pattern as that of DXR in AH66P cells (Asakura et al, 1997). It
was suggested that the conjugates GSH-DXR, EAG-DXR and
ESG-DXR were not recognized by the P-gp efflux pump because
of their strong acidity compared with DXR or triGly-DXR. This
result supports the notion that P-gp extrudes hydrophobic and
mostly cationic compounds from cancer cells at physiological pH
(Gottesman and Pastan, 1993).
Although GSH-DXR accumulated in AH66P cells at a lower
concentration than did DXR, GSH-DXR showed 170-fold more
cytotoxic activity than DXR. The conjugates with the substitution
of amino acids for cysteine, EAG-DXR and ESG-DXR, demon-
strated a significant reduction in the cytotoxic efficacy in tumour
cells relative to GSH-DXR without any significant difference in
intracellular drug concentration between GSH-DXR and EAG- or
ESG-DXR. This result indicates that the thiol group ofGSH-DXR
plays an important role in the expression ofincreased cytotoxicity.
As the treatment of AH66P cells with GSH-DXR caused a 45%
reduction in cellular GSH concentration compared with non-
treated cells, GSH-DXR might contribute to the increasing cyto-
toxicity by inhibition of the GSH/GST detoxification system apart
from intercalation of DXR with DNA. However, following a 96-h
treatment of the cells with 4 gM BSO, reduction in the cellular
GSH content, from 14.75 to 2.94 nmol mg-' protein
of whole-cell homogenate in AH66P and from 30.45 to
5.16 nmol mg-' protein of whole-cell homogenate in AH66DR,
did not show any enhancement of cytotoxic efficacy of the drugs.
An approximately 80% reduced cellular GSH content was prob-
ably not sufficient to suppress GSH/GST-mediated drug detoxifi-
cation because the reduced GSH concentration was still almost
equal to that in normal rat liver (4.95 nmol mg-' protein ofwhole-
tissue homogenate) measured in our experiment.
The activity ofGST in cell extracts prepared from either AH66P
or AH66DR cells was inhibited markedly by the addition ofGSH-
DXR or EAG-DXR, and their IC50 values for the GST activity
were 1.3 gM and 10 gM respectively in the extract from AH66P
cells and 1.2 gM and 11JIM respectively in the extract from
AH66DR cells. It has been reported that some compounds in
which the alkyl group was coupled to the thiol of GSH inhibited
GST activity (Lyttle et al, 1994). Although GSH-DXR in the
present study consisted of DXR conjugated to the amino group of
GSH and not to thiol, the conjugate showed the potent inhibition
ofthe GST activity. In contrast to this result, the addition ofGSH-
DXR, at the concentration to exhibit almost the same cytotoxici-
ties, to cultured AH66P and AH66DR cells did not induce any
significant decrease in GST activity compared with that in cells
cultured without GSH-DXR. The discrepancy between these two
results might be derived from the fact that the GSH-DXR concen-
tration in the cells was diluted 2500-fold with GST assay medium
and consequently GST activity was not inhibited by such a low
concentration of GSH-DXR when GST activity was measured in
the extracts from GSH-DXR-treated cells. As about 14% of the
added GSH-DXR was accumulated in AH66DR cells during the
24-h incubation period, the intracellular drug concentration was
estimated to be 1.4gM (1.4 mmol kg-' wet weight ofthe cells) by
the addition of 0.2 nmol GSH-DXR to 2 ml of the culture media
containing 20 mg wet weight of AH66DR cells. Under these
conditions, the treatment of AH66DR cells with 100 nM
(0.2 nmol 2 ml-') GSH-DXR was sufficient to inhibit the intracel-
lular (in situ) GST activity (approximately 50% inhibition).
Similarly, by treating AH66P cells with 10 nM GSH-DXR, the
intracellular concentration of GSH-DXR was estimated to be
0.15 ,UM. This concentration ofGSH-DXR was equivalent to 20%
inhibitory concentration of GST activity. Moreover, the cytotoxic
efficacy of DXR, BSA-DXR or GSH-DXR was further increased
approximately two- to ninefold relative to the control when the
cells were cotreated with both drugs and tributyltin acetate, an
inhibitor of GST. The degree of enhancement of the cytotoxic
activity of GSH-DXR was, however, smaller than that of DXR or
BSA-DXR after treatment with tributyltin acetate. This result
mightexplain why the inhibition ofGST activity induced by GSH-
DXR treatment had already increased the cytotoxicity before the
addition of tributyltin acetate, suggesting that the cytotoxic effect
of these drugs was partly suppressed by the action of GST. EAG-
DXR also showed moderate, but significant inhibition of the
enzyme activity. In contrast, ESG-DXR did not exhibit any
inhibitory effect on GST activity, but the cytotoxicity of ESG-
DXR was 60-fold higher than that of DXR against AH66P cells.
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The difference in cytotoxic activity against AH66P cells between
DXR and ESG-DXR, or ESG-DXR and EAG-DXR or GSH-DXR
needs to be explained in terms of other relevant factors, such as
DNA topoisomerase II (Beck, 1989; Deffie et al, 1989; Isabella et
al, 1991) or reactive oxygen species (Berlin and Haseltine, 1981;
Hockenbery et al, 1993), for which further studies are needed.
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ABBREVIATIONS
DXR, doxorubicin; GSH, reduced glutathione; GSH-DXR,
doxorubicin conjugated with glutathione; GST, glutathione S-
transferase; IC50, 50% inhibitory concentration for GST activity;
MDR, multidrug resistance; P-gp, P-glycoprotein; BSA, bovine
serum albumin; MTT, 3-(4,5-dimethyl-2-thiazolyl) 2,5-diphenyl-
tetrazolium bromide; CDNB, 1-chloro-2,4-dinitrobenzene; BSO,
buthionine sulphoximine; triGly, glycylglycylglycine; EAG, y-
glutamylalanylglycine; ESG, y-glutamylserylglycine.
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